Navigation Links
Women Taking Oestrogen Therapy Showed Reduced Coronary Artery Calcification

The Research study found that younger menopausal women (aged 50-59) who received a standard dose of oral conjugated estrogens had significantly less coronary artery calcification at the end of the study period compared with those taking placebo. Coronary artery calcification is a marker of plaque in the arteries and a predictor of future cardiovascular events.

In the five years since the WHI study ended, new data have emerged that help put the initial findings into perspective. These results showed that in these younger menopausal women, estrogen therapy reduced calcified plaque buildup in the arteries, says Howard Hodis, M.D., Professor of Medicine and Preventive Medicine; Director, Artherosclerosis Research Unit, University of Southern California.

These data support initiation of estrogen therapy, where indicated when a woman first enters menopause and begins experiencing symptoms and bone loss.

Wyeth is unaware of any coronary artery calcification data for women taking estrogen plus progestin. The investigators did not study coronary artery calcification in women who were over 60 at the beginning of the study.

This study found no apparent increase in coronary heart disease for women who initiated hormone therapy within 10 years of menopause; and a statistically significant reduction in total mortality among women aged 50-59 in the group receiving hormone therapy compared with those in the placebo group.

The recent pooled analysis published in JAMA provides reassurance about coronary artery disease to newly menopausal women considering estrogen plus progestin therapy or estrogen alone therapy for symptom relief and prevention of postmenopausal bone loss.

The recent pooled analysis published in JAMA provides reassurance about coronary artery disease to newly menopausal women considering estrogen plus progestin therapy or estrogen alone therapy for symptom relief and prevention of postmenopausal bone loss.

The data published today in NEJM provide additional evidence for women considering estrogen alone therapy, says Joseph Camardo, M.D., Senior Vice President of Global Medical Affairs for Wyeth Pharmaceuticals. We hope this information can help clarify the clinical perspective for women who choose hormone treatment for menopausal symptoms and prevention of osteoporosis.

The authors conclude, Hormone therapy should not be initiated (or continued) for the express purpose of preventing cardiovascular disease in either younger or older postmenopausal women. The authors further state, The current recommendations from many organizations that hormone therapy be limited to the treatment of moderate to severe menopausal symptoms, with the lowest effective dose used for the shortest duration necessary, remain appropriate. Wyeth continues to support the use of hormone therapy.

Hormone therapy is not appropriate for all women. Women experiencing menopausal symptoms are encouraged to speak with their health care professional to determine whether hormone therapy might be the right treatment option for them.


'"/>




Related medicine news :

1. Women suffer from sexual dysfunction too
2. Women find difficulty in calling it Quits
3. Women recognise faces better
4. Women more susceptible to brain damage from ecstasy
5. Good News For Women With Gestational Diabetes
6. Unsatisfactory Grade On Womens Health Issues
7. Risk for Pregnant Women
8. Womens strong sense of smell
9. Women need to exercise more to prevent obesity
10. Women benefit from consuming fish
11. Women are at risk with raised cholesterol
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: